Zinman Jon 4

What Happened

• Jon Zinman, a director of Keenova Therapeutics plc, had 4,882 restricted stock units (RSUs) settle into 4,882 ordinary shares on June 2, 2026 (reported June 4, 2026). The transaction is reported as an exercise/conversion of a derivative (code M) and shows a disposal at $0.00, indicating no sale for cash. The shares were held directly by JZ Advisors LLC, an entity 100% owned and managed by Zinman.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-04.
• Shares converted/settled: 4,882 ordinary shares (1 share per RSU as noted).
• Price/proceeds: $0.00 on the disposal line — this reflects a transfer, not a market sale; no cash proceeds reported.
• Post-transaction holdings: The 4,882 shares are held directly by JZ Advisors LLC (owned by Zinman). The filing does not disclose Zinman’s total aggregate holdings beyond this transfer.
• Relevant footnotes: RSUs were granted Aug 14, 2025 and vest on the earlier of the first anniversary of grant or the issuer’s next annual general meeting (per filing). The filing also serves as notice under the Companies Act 2014.

Context

• This was a conversion/settlement of RSUs into shares followed by a transfer to a related entity (a common post-vesting administrative move), not an open-market sale or purchase. Because no cash changed hands, it should not be read as a bullish or bearish market signal. The Form 4 was filed two days after the transaction, consistent with typical insider reporting timelines.